Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of SKYWAY remain on track; Week 16 topline readouts expected in Q4 2026 SKYLINE platform trial in ulcerative colitis (UC) continues to enroll ahead of schedule; Part A readouts to begin in Q2 2026 WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NAS ...